The Anti-CD22 CAR-T Cells are produced by high-titer lentiviral transduction of human primary CD4+and CD8+ T cells using the Anti-CD22 CAR Lentivirus (Clone m971 ScFv-CD8-4-1BB-CD3zeta) (#78608). These ready-to-use CAR-T cells express an anti-CD22 CAR consisting of the ScFv (Single chain fragment variable) of anti-CD22(clone m971) linked to a 2nd generation CAR (Chimeric Antigen Receptor) containing CD8 hinge and transmembrane domains, and the 4-1BB and CD3zeta signaling domains (Figure 1). These CAR-T cells have been validated using flow cytometry (to determine the CAR expression) and co-culture cytotoxicity assays. Figure 1. Construct diagram showing components of the anti-CD22 CAR expressed in Anti-CD22 CAR-T Cells.